Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | PRKX | P51817 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875440 | 0.90 | KDR (0.42) | BRAFKDM4EMAPTPDE4APDE4B | |
| SCHEMBL16430764 | 0.80 | MEN1 (0.47) | BRAFSCN9ANR3C1CDC7DAPK3 | |
| SCHEMBL3874678 | 0.78 | KDM4E (0.63) | KDM4EPOLBMAPTGAA | |
| SCHEMBL1122587 | 0.76 | BRAF (0.55) | BRAFSCN9ANR3C1KDM4EMAPT | |
| SCHEMBL3873190 | 0.75 | KCNA3 (0.45) | BRAFSCN9ANR3C1KDM4E | |
| SCHEMBL1285186 | 0.75 | CYP1A2 (0.44) | BRAFKDM4EMAPTGAA | |
| SCHEMBL1040298 | 0.74 | TRPV1 (0.63) | — | |
| SCHEMBL3874602 | 0.73 | RHEB (0.55) | BRAFSCN9AKDM4EMAPT | |
| SCHEMBL15485307 | 0.72 | IDO1 (0.44) | BRAFMAP4K4MAPT | |
| SCHEMBL15490439 | 0.72 | SMN1; SMN2 (0.41) | BRAFMAP4K4KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1720868-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077944-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | BRAF 735/4885SCN9A 838/4885NR3C1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.